10-Q quarterly report · filed Nov 4, 2026

Edgewise Therapeutics, Inc. (EWTX) Q3 2026 10-Q Quarterly Report

Short answer

Edgewise Therapeutics, Inc. (EWTX) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026.

Q3 2026 key financials · XBRL

Net income
$1.2B
+2967.6% YoY · +2134.2% QoQ
EPS (diluted)
$9.85
+2692.1% YoY · +1958.5% QoQ

Source: XBRL data from the Edgewise Therapeutics, Inc. (EWTX) Q3 2026 10-Q on SEC EDGAR. USD.

Edgewise Therapeutics, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • No product revenue; net income $1,166.2M vs $40.7M loss YoY, driven by $1,348.1M Sevasemten-sale gain
  • Operating margin not meaningful: operating loss $46.1M vs $46.9M YoY, while effective tax rate was 11.8%
  • Best program: EDG-7500 R&D $6.8M vs $4.5M; worst: Sevasemten $2.5M vs $13.6M
  • Cash, equivalents and securities $1,743.9M vs $530.1M at December 31, 2025; operating cash outflow $163.3M
  • Phase 3 EDG-7500 trial planned for Q4 2026; GRAND CANYON study missed endpoints, threatening milestone payments

Risk Factors

  • Newly added tax risk: Sevasemten Sale may create material cash tax obligations despite approximately $319.7 million federal NOL carryforwards
  • Most materially updated regulatory risk: FDA reorganization and workforce reductions could delay reviews, inspections and clinical development timelines
  • Competitive risk: Cytokinetics received Myqorzo approvals in the US, Europe and certain Asian countries during late 2025 and early 2026
  • Financial risk: $1,743.9 million in cash, equivalents and marketable securities expected to fund operations for at least 12 months
  • Legal compliance risk: GDPR violations can trigger fines up to €20,000,000 or 4% of worldwide annual turnover

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Edgewise Therapeutics, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.